NCT06427057View on ClinicalTrials.gov

A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2027

Conditions
Urinary System Tumor
Interventions
DRUG

Cadonilimab plus chemotherapy

AK104 (10mg/kg ,Q3W，intravenously) plus chemotherapy（e.g. gemcitabine or albumin paclitaxel，dosage based on guidelines or instructions）

DRUG

Cadonilimab plus TKI

Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus TKI（e.g. sunitinib, pezopanib，dosage based on guidelines or instructions)

All Listed Sponsors
lead

Tongji Hospital

OTHER